| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.anglifesciences.com | |
| Market Cap | 104.39 Cr. | |
| Enterprise Value(EV) | 171.99 Cr. | 2022-09 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | 7.35 | Trailing Twelve Months Ending 2022-12 |
| Price-Earning Ratio (PE) | 10.88 | Trailing Twelve Months Ending 2022-12 |
| Industry PE | 31.87 | Trailing Twelve Months Ending 2022-12 |
| Book Value / Share | 69.67 | Trailing Twelve Months Ending 2022-12 |
| Price to Book Value | 1.15 | Calculated using Price: 80.00 |
| Dividend Yield | 1.00 | Period Ending 2022-03 |
| No. of Shares Subscribed | 1.31 Cr. | 13,058,287 Shares |
| FaceValue | 10 | |
| Company Profile | ||
| The company is ISO-9001:2008 certified and has the modern & sophisticated plant, equipments, technique and manpower. The planning and construction of plant has been done to conform to the regulatory requirements as per the norms of WHO G.M.P. and G.L.P. as per schedule-M (revised). They manufacture their products in compliance with GMP requirements. They have dedicated area, machinery, facilities and advanced equipments for manufacturing of B-Lactum & Non-B Lactum products as per GMP Norms. The production block provides appropriate personnel and material flow. As per GMP norms, all the production processes are documented and validated to establish the accuracy of the procedures and the control measures. The Company's production capacity is 700 Lakhs Pcs per annum on per shift basis. Their products include sterile dry powder vials for Anti Biotics, Anti Ulcerant, Gluco corticoid and Anti inflammatory, Anti malarial and Anesthetic. | ||
| 1 Day |
|
-3.04% |
| 1 Week |
|
-3.66% |
| 1 Month |
|
+3.69% |
| 3 Month |
|
-32.66% |
| 6 Month |
|
-47.02% |
| 1 Year |
|
-62.02% |
| 2 Year |
|
+135.16% |
| 5 Year |
|
+279.87% |
| 10 Year |
|
| 1 years | 2022-03 | |
| Return on Equity (%) | 48.13 | |
| Return on Capital Employed (%) | 39.14 | |
| Return on Assets (%) | 14.06 |
| Particulars | 2 years | 2022-03 Rs. Cr. | 2022-09* Rs. Cr. |
| Shh. Funds | 84 | 91 | |
| Non Curr. Liab. | 37 | 30 | |
| Curr. Liab. | 166 | 164 | |
| Minority Int. | |||
| Equity & Liab. | 287 | 285 | |
| Non Curr. Assets | 94 | 90 | |
| Curr. Assets | 193 | 196 | |
| Misc. Exp. not W/O | |||
| Total Assets | 287 | 285 |
| Particulars | 2 years | 2022-03 Rs. Cr. | 2022-12 Rs. Cr. TTM |
| Net Sales | 354 | 276 | |
| Other Income | 1 | 1 | |
| Total Income | 355 | 277 | |
| Total Expenditure | -286 | -239 | |
| PBIDT | 69 | 38 | |
| Interest | -9 | -14 | |
| Depreciation | -6 | -9 | |
| Taxation | -13 | -6 | |
| Exceptional Items | |||
| PAT | 40 | 10 | |
| Minority Interest | |||
| Share Associate | |||
| Other Related Items | |||
| Consolidated Net Profit | 40 | 10 | |
| Adjusted EPS | 31 | 7 |
| Particulars | 1 years | 2022-03 Rs. Cr. |
| Cash Fr. Operatn. | 25 | |
| Cash Fr. Inv. | -44 | |
| Cash Fr. Finan. | 20 | |
| Net Change | 0 | |
| Cash & Cash Eqvt | 0 |
|
Wed, 15 Mar 2023
Announcement under Regulation 30 (LODR)-Newspaper Publication Pursuant to Regulation 30 & 47 of SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015 please find enclosed herewith copies of Newspaper Advertisement published on 13tt-March 2023 one in the English Newspaper having nationwide circulation- Business Standard and one in Vernacular Newspaper - Desh Sewak intimating the shareholders about Extra Ordinary General Meeting of our company to be heid on O1* April 2023 at 12:00 P.M through Video Conferencing/other Audio-Visual Means (OAVM). |
|
Fri, 10 Mar 2023
Notice Of Extra Ordinary General Meeting Of The Company. Pursuant to Regulation 30 read with Part A of Schedule III we are enclosing herewith a copy of notice of the Extra Ordinary General Meeting (EGM) of ANG Lifesciences India Ltd ("the Company) to be held on Saturday 01st April 2023 at 12:00 p.m. (IST) through Video Conferencing ("VC")/Other Audio-Visual Means ("OAVM").The said Notice is being sent only through e-mails to the shareholders of the Company at their registered e-mail addresses and the same has also been uploaded on the website of the Company at www.anglifesciences.comThe Company has fixed Saturday 25th March 2023 as the "Cut-off-Date" for the purpose of determining the eligibility of the members entitled to vote by remote e-voting. Those shareholders holding shares either in dematerialized form or in physical form as on the close of business hours on Saturday 25th March 2023 will be entitled to avail the facility of remote e-voting as well as voting at the EGM. |
|
Fri, 10 Mar 2023
Notice Of Extra Ordinary General Meeting Of The Company. Due to some inadvertent error we submitted the incorrect file of Notice of EGM. Therefore we hereby submitted the final copy of notice of EGM. The EGM will be held on Saturday 01st April 2023 at 12:00 p.m. (IST) through Video Conferencing ("VC")/Other Audio-Visual Means ("OAVM"). |
| Fri, 24 Mar 2023 |
High Delivery Percentage
|
Close Crossing Last Week Low
|
Closing Below Previous Low
|
Making Lower Lows for 3 days
|
Close Within 52 Week Low Zone
|
Equities
M.F.
Sectors